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Introduction
Human biomonitoring (HBM) measures the 
levels of environmental chemicals or their 
metabolites in easily accessible body fluids 
and tissues (Angerer et al. 2006), and reflects 
all routes of uptake—oral, dermal, inhala-
tive—and all relevant sources. The power of 
HBM to identify spatial and temporal trends 
in human exposures has contributed success-
fully to initiate policy measures and to focus 
on protection of susceptible populations such 
as children and pregnant mothers. The ban of 
lead from gasoline was triggered by elevated 
blood lead levels in the National Health and 
Nutrition Examination Survey (NHANES) 
(Pirkle et al. 1994). Results of the German 
Environmental Survey (GerES) led to recom-
mendations to avoid mercury-containing 
amalgam teeth fillings in children (Becker 
et al. 2013) and contributed to the restric-
tion of phthalate use in plastics (Göen et al. 
2011). Increasing levels of polybrominated 
diphenyl ethers (PBDEs) in maternal milk 
samples of Sweden have led to the gradual 
phasing out of lower brominated congeners 
of PBDEs (Meironyté et al. 1999). 
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Background: For Europe as a whole, data on internal exposure to environmental chemicals do not 
yet exist. Characterization of the internal individual chemical environment is expected to enhance 
 understanding of the environmental threats to health.
oBjectives: We developed and applied a harmonized protocol to collect comparable human 
 biomonitoring data all over Europe.
Methods: In 17 European countries, we measured mercury in hair and cotinine, phthalate metabolites, 
and cadmium in urine of 1,844 children (5–11 years of age) and their mothers. Specimens were collected 
over a 5-month period in 2011–2012. We obtained information on personal characteristics, environment, 
and lifestyle. We used the resulting database to compare concentrations of exposure biomarkers within 
Europe, to identify determinants of exposure, and to compare exposure biomarkers with health-
based guidelines.
results: Biomarker concentrations showed a wide variability in the European population. However, 
levels in children and mothers were highly correlated. Most biomarker concentrations were below the 
health-based guidance values.
conclusions: We have taken the first steps to assess personal chemical exposures in Europe as a whole. 
Key success factors were the harmonized protocol development, intensive training and capacity building for 
field work, chemical analysis and communication, as well as stringent quality control programs for chemical 
and data analysis. Our project demonstrates the feasibility of a Europe-wide human biomonitoring 
framework to support the decision-making process of environmental measures to protect public health.
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Experience with human biomonitoring 
in the general population differs among 
European countries, with long-standing tradi-
tions in countries such as Germany (Becker 
et al. 2008), France (Fréry et al. 2012), the 
Czech Republic (Cerná et al. 2012), Belgium 
(Flanders) (Schoeters et al. 2012), and Spain 
(Pérez-Gómez 2013), whereas other countries 
have no experience at all.
The “European Environment and Health 
Action Plan” (European Commission 2004) 
prioritized the need to harmonize HBM in 
Europe to allow comparison of data among 
countries and provide tools for follow-up 
of temporal and spatial trends in chemical 
exposures. The preparation of the protocol, 
including the selection of chemicals and 
study populations, started in 2005 with the 
Expert team to Support BIOmonitoring 
in Europe (ESBIO) project. With the 
funding of the Consortium to Perform 
Human Biomonitoring on a European 
Scale (COPHES) and its demonstration 
project DEMOCOPHES, the feasibility of 
a harmonized HBM approach was tested 
(Joas et al. 2012). COPHES designed the 
final protocol and made justified choices 
for exposure biomarkers, sample size, and 
recruitment strategy. DEMOCOPHES 
allowed 17 European countries to put this 
protocol into practice. Selected chemicals 
included phthalates that are present in some 
consumer products and food packaging 
(Koch and Calafat 2009), mercury and 
cadmium as ubiquitous developmental toxi-
cants of concern (Grandjean and Landrigan 
Figure 1. Overview of GMs (95% CIs) of biomarker concentrations (μg/L for urinary markers and μg/g for mercury in hair) in children and mothers of the partici-
pating countries. Country codes: BE, Belgium; CH, Switzerland; CY, Cyprus; CZ, Czech Republic; DE, Germany; DK, Denmark; ES, Spain; HU, Hungary; IE, Ireland; 
LU, Luxembourg; PL, Poland; PT, Portugal; RO, Romania; SE, Sweden; SI, Slovenia; SK, Slovak Republic; UK, United Kingdom. NA, no biomarker data available. For 
phthalate abbeviations, see Table 2. All data for children are adjusted for age and sex; urinary metabolites are additionally adjusted for urinary creatinine; all data 
in mothers are adjusted for age; urinary metabolites are additionally adjusted for urinary creatinine; urinary cadmium is additionally adjusted for smoking. Light 
blue: GM of country significantly below European GM. Dark blue: GM of country is significantly above European GM. White: no significant difference between GM 
of country and European GM. For European GMs, see Table 2.
Children BE CH CY CZ DE DK ES HU IE LU PL PT RO SE SI SK UK
Mercury 0.204  
(0.172, 
0.241)
0.076  
(0.065, 
0.090)
0.326  
(0.257, 
0.413)
0.098  
(0.083, 
0.116)
0.055  
(0.046, 
0.065)
0.250 
(0.211, 
0.295)
0.884  
(0.747, 
1.046)
0.025  
(0.021, 
0.029)
0.097  
(0.082, 
0.114)
0.181  
(0.142, 
0.229)
0.070  
(0.060, 
0.083)
1.033  
(0.873, 
1.222)
0.085  
(0.072, 
0.101)
0.181  
(0.153, 
0.214)
0.169  
(0.142, 
0.200)
0.092  
(0.078, 
0.109)
0.192  
(0.163, 
0.228)
Cadmium 0.046  
(0.040, 
0.052)
0.081  
(0.071, 
0.092)
0.114  
(0.096, 
0.261)
0.117  
(0.104, 
0.133)
NA 0.024  
(0.021, 
0.027)
0.047  
(0.041, 
0.053)
0.129  
(0.113, 
0.146)
0.068  
(0.060, 
0.077)
0.154  
(0.129, 
0.184)
0.134  
(0.118, 
0.152)
0.045  
(0.039, 
0.051)
0.026  
(0.023, 
0.029)
0.090  
(0.079, 
0.103)
0.077  
(0.068, 
0.087)
0.144  
(0.127, 
0.163)
0.167  
(0.147, 
0.191)
Cotinine 0.629  
(0.517, 
0.766)
0.508  
(0.418, 
0.619)
0.842  
(0.638, 
1.111
1.602  
(1.316, 
1.950)
0.305  
(0.251, 
0.371)
0.658  
(0.541, 
0.801)
1.485  
(1.219, 
1.810)
1.776  
(1.460, 
2.161)
0.708  
(0.582, 
0.862)
0.397  
(0.301, 
0.524)
1.568  
(1.288, 
1.909)
1.093  
(0.897, 
1.333)
1.942  
(1.943, 
1.597)
0.202  
(0.165, 
0.246)
0.529  
(0.434, 
0.644)
1.085  
(0.892, 
1.320)
0.661  
(0.542, 
0.806)
DEHP 37.3  
(32.9, 
42.2)
28.1  
(24.9, 
31.9)
25.0  
(21.0, 
29.8)
71.1  
(62.7, 
80.5)
39.5  
(34.9, 
44.8)
40.9  
(36.1, 
46.4)
73.4  
(64.7, 
83.2)
58.7  
(51.8, 
66.5)
59.6  
(52.6, 
67.5)
25.8  
(21.7, 
30.8)
76.4  
(67.4, 
86.6)
48.2  
(42.5, 
54.6)
74.0  
(65.4, 
83.8)
49.9  
(43.9, 
56.6)
46.3  
(40.8, 
53.4)
82.7  
(73.0, 
93.7)
37.5  
(33.0, 
42.5)
MEP 26.7  
(22.3, 
32.0)
19.7  
(16.5, 
23.6)
41.2  
(31.9, 
53.1)
34.4  
(28.7, 
41.1)
23.1  
(19.3, 
27.7)
22.1  
(18.5, 
26.5)
208.3  
(173.7, 
249.8)
45.4  
(37.9, 
54.3)
42.5  
(35.5, 
50.9)
26.8  
(20.8, 
34.6)
46.9  
(39.1, 
56.2)
50.2  
(41.8, 
60.2)
34.8  
(29.1, 
41.7)
33.3  
(27.8, 
40.0)
40.2  
(33.5, 
48.1)
37.5  
(31.3, 
44.9)
16.9  
(14.1, 
20.3)
MBzP 9.0  
(7.5, 
10.6)
5.1  
(4.3, 
6.1)
3.7  
(2.9, 
4.7)
9.1  
(7.6, 
10.8)
6.6  
(5.5, 
7.8)
8.0  
(6.7, 
9.4)
14.6  
(12.3, 
17.3)
7.3  
(6.2, 
8.7)
5.9  
(5.0, 
7.0)
5.2  
(4.1, 
6.6)
9.3  
(7.9, 
11.1)
8.1  
(6.8, 
9.6)
4.1  
(3.5, 
4.9)
23.1  
(19.4, 
27.5)
7.9  
(6.6, 
9.4)
7.9  
(6.6, 
9.4)
4.2  
(3.5, 
4.9)
MnBP 39.4  
(34.9, 
44.6)
20.1  
(17.8, 
22.8)
20.6  
(17.3, 
24.6)
NA 46.4  
(41.0, 
52.5)
33.6  
(29.7, 
38.1)
52.7  
(46.5, 
59.7)
NA 28.5  
(25.2, 
32.2)
28.2  
(23.7, 
33.6)
90.4  
(80.0, 
102.3)
33.3  
(29.4, 
37.7)
43.2  
(38.2, 
48.8)
NA 38.0  
(33.5, 
42.9)
NA 26.4  
(23.3, 
29.9)
MiBP 59.2  
(51.9, 
67.5)
20.5  
(18.0, 
23.4)
51.8  
(43.0, 
62.3)
NA 41.4  
(36.3, 
47.2)
62.2  
(54.5, 
71.0)
63.8  
(55.9, 
72.9)
NA 45.4  
(39.8, 
51.7)
36.9  
(30.6, 
44.4)
108.3  
(95.0, 
123.5)
40.3  
(35.3, 
46.1)
51.1  
(44.8, 
58.3)
NA 55.0  
(48.2, 
62.7)
NA 30.3  
(26.5, 
34.6)
Mothers BE CH CY CZ DE DK ES HU IE LU PL PT RO SE SI SK UK
Mercury 0.368  
(0.313, 
0.431)
0.153  
(0.131, 
0.180)
0.462  
(0.369, 
0.578)
0.156  
(0.133, 
0.183)
0.107  
(0.092, 
0.126)
0.391  
(0.333, 
0.458)
1.486  
(1.267, 
1.744)
0.039  
(0.033, 
0.045)
0.162  
(0.139, 
0.190)
0.387  
(0.308, 
0.485)
0.135  
(0.116, 
0.159)
1.200  
(1.023, 
1.406)
0.100  
(0.085, 
0.117)
0.252  
(0.215, 
0.295)
0.255  
(0.217, 
0.299)
0.132  
(0.112, 
0.154)
0.153  
(0.130, 
0.180)
Cadmium 0.224  
(0.197, 
0.255)
0.224  
(0.197, 
0.255)
0.183  
(0.153, 
0.219)
0.259  
(0.228, 
0.295)
NA 0.132  
(0.116, 
0.150)
0.212  
(0.187, 
0.241)
0.183  
(0.161, 
0.207)
0.296  
(0.261, 
0.336)
0.249  
(0.208, 
0.298)
0.453  
(0.399, 
0.514)
0.186  
(0.164, 
0.211)
0.187  
(0.164, 
0.212)
0.175  
(0.154, 
0.199)
0.289  
(0.255, 
0.329)
0.306  
(0.269, 
0.348)
0.267  
(0.234, 
0.304)
Cotinine 1.257  
(0.736, 
2.147)
0.844  
(0.493, 
1.446)
2.825  
(1.329, 
6.002)
3.773  
(2.211, 
6.441)
1.005  
(0.588, 
1.717)
1.871  
(1.091, 
3.209)
9.586  
(5.597, 
16.42)
7.187  
(4.209, 
12.27)
3.863  
(2.266, 
6.585)
0.557  
(0.260, 
1.193)
6.219  
(3.644, 
10.61)
10.92  
(6.401, 
18.64)
14.92  
(8.702, 
25.57)
1.803  
(1.056, 
3.080)
1.790  
(1.048, 
3.058)
2.819  
(1.653, 
4.809)
0.843  
(0.489, 
1.452)
DEHP 21.7  
(19.0, 
24.8)
20.4  
(17.8, 
23.3)
16.8  
(13.9, 
20.3)
37.3  
(32.6, 
42.6)
21.1  
(18.5, 
24.1)
24.0  
(21.0, 
27.4)
43.4  
(38.0, 
49.6)
34.0  
(29.7, 
38.8)
32.3  
(29.7, 
38.8)
15.9  
(13.2, 
19.3)
43.9  
(38.4, 
50.2)
37.2  
(32.6, 
42.5)
51.5  
(45.0, 
58.9)
28.4  
(24.8, 
32.4)
28.1  
(24.6, 
32.1)
39.4  
(34.5, 
45.0)
15.5  
(13.5, 
17.8)
MEP 37.1  
(30.1, 
45.8)
31.2  
(25.2, 
38.5)
87.7  
(65.2, 
117.9)
59.2  
(48.0, 
73.0)
38.5  
(31.2, 
47.6)
37.3  
(30.2, 
46.1)
160.0  
(129.5, 
197.6)
50.9  
(41.2, 
62.8)
55.2  
(44.8, 
68.1)
36.4  
(27.0, 
49.1)
42.5  
(34.5, 
52.5)
55.9  
(45.3, 
68.9)
44.2  
(35.8, 
54.7)
46.5  
(37.7, 
57.4)
46.8  
(37.9, 
57.8)
52.2  
(42.3, 
64.4)
27.4  
(22.1, 
33.9)
MBzP 6.5  
(5.6, 
7.7)
3.9  
(3.3, 
4.6)
2.4  
(1.9, 
3.0)
4.7  
(4.0, 
5.6)
4.5  
(3.8, 
5.2)
4.5  
(3.8, 
5.2)
8.5  
(7.2, 
9.9)
4.3  
(3.7, 
5.1)
3.4  
(2.9, 
4.0)
3.6  
(2.8, 
4.5)
4.5  
(3.9, 
5.3)
5.6  
(4.8, 
6.6)
2.5  
(2.1, 
2.9)
13.8  
(11.8, 
16.2)
4.4  
(3.8, 
5.2)
4.4  
(3.8, 
5.2)
1.7  
(1.5, 
2.0)
MnBP 30.5  
(27.1, 
34.4)
13.9  
(12.3, 
15.7)
16.1  
(13.6, 
19.1)
NA 29.7  
(26.4, 
33.5)
21.6  
(19.2, 
24.4)
30.8  
(27.3, 
34.7)
NA 20.2  
(18.0, 
22.8)
18.3  
(15.4, 
21.7)
48.2  
(42.8, 
54.4)
22.3  
(19.8, 
25.1)
27.1  
(24.0, 
30.6)
NA 23.8  
(21.1, 
26.8)
NA 13.1  
(11.6, 
14.9)
MiBP 38.6  
(34.1, 
43.6)
14.4  
(12.7, 
16.3)
43.7  
(36.8, 
52.0)
NA 24.6  
(21.8, 
27.8)
41.6  
(36.7, 
47.1)
37.0  
(32.7, 
41.8)
NA 26.5  
(23.4, 
29.9)
21.1  
(17.7, 
25.1)
53.6  
(47.4, 
60.6)
28.4  
(25.1, 
32.1)
34.7  
(30.6, 
39.2)
NA 34.9  
(30.8, 
39.4)
NA 17.6  
(15.5, 
19.9)
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2006), and urinary cotinine (Avila-Tang 
et al. 2013) as a biomarker for exposure to 
cigarette smoke; urinary creatinine was 
included as a measure for urine dilution. 
Young children and mothers of childbearing 
age were selected as vulnerable populations. 
Mercury in hair (Budtz-Jørgensen et al. 2004) 
and urinary cadmium (Akerstrom et al. 2013) 
are markers of chemicals that accumulate in 
the body over a longer time period; urinary 
phthalate metabolites (Wittassek et al. 
2011) and cotinine (Avila-Tang et al. 2013) 
measured in spot urine samples represent 
short-term exposure.
Methods
Study design and participants. The cross-
sectional survey was designed to include 120 
children (5–11 years of age) and their mothers 
in each country, with 60 mother–child pairs 
each in Cyprus and Luxembourg because 
of the countries’ smaller populations. We 
sampled the children and mothers between 
September 2011 and February 2012, either 
through schools or population registries. 
These were convenience samples with equal 
shares in an urban and a rural location as 
defined according to regional standards. We 
included only healthy children and mothers 
(no metabolic disturbances), who had suffi-
cient knowledge of the local language and 
had been living at least for 5 years at the 
sampling location. Details and rationale for 
the study design are reported by Becker et al. 
(2014). The sample size allowed us to estimate 
preliminary country-specific reference values 
(Poulsen et al. 1997) and a minimally impor-
tant difference in mean biomarker values of 
30% between countries (α = 0.05, β = 0.80). 
Fieldworkers from the national study centers 
were trained and instructions were provided 
centrally and adapted at national level to each 
country’s language, cultural conventions, and 
ethical and legal requirements. Information 
on characteristics of the study population and 
potential determinants of internal exposure 
was obtained through personalized interviews 
using questionnaires. Standard operation 
procedures (SOPs) to collect hair and morning 
urine samples were implemented (Becker 
et al. 2014). The study was approved by ethics 
committees in each country (for a list of ethics 
committees per country, see Supplemental 
Material, Table S1); mothers and children gave 
written informed consent or assent, respec-
tively. All procedures followed the national 
data protection requirements including 
 notification to data protection authorities.
Chemical analysis. We established a 
Quality Assurance Program to guarantee 
the quality and comparability of analytical 
results among laboratories (Schindler et al. 
2014). Each participating laboratory received 
SOPs for sampling, sample conservation, 
and chemical analysis (Becker et al. 2014; 
Schindler et al. 2014). We organized two 
interlaboratory comparison investigations 
and two external quality assessment schemes 
(ICI/EQUAS) with native control material 
(hair, urine) sent to all laboratories willing 
to participate. To evaluate the ICIs, we 
calculated consensus values as the mean of 
the results of the participating laboratories 
(after exclusion of outliers). To evaluate 
the EQUAS, we calculated assigned values 
(target values) from the results of experienced, 
renowned reference laboratories. Laboratories 
were defined as “qualified laboratories” if they 
participated successfully in at least one ICI 
and one EQUAS round or in two EQUAS 
rounds (Schindler et al. 2014). The number 
of laboratories that qualified for each analyte 
was as follows: mercury, 15; cotinine, 9; 
cadmium, 14; phthalate metabolites [mono-
ethylhexyl phthalate (MEHP), 2-ethyl-
5-hydroxyhexyl phthalate (5OH-MEPH), 
2-ethyl-5-oxohexyl phthalate (5oxo-MEHP), 
monoethyl phthalate (MEP), monobenzyl 
phthalate (MBzP), mono-n-butyl phthalate 
(MnBP), monoisobutyl phthalate (MiBP)], 7; 
and creatinine, 14.
Database management and statistical 
analysis. National data centers applied uniform 
rules for database construction by using one 
centrally developed code book with predefined 
variable names, unities, formats, and coding 
rules. Quality controls on the data were 
performed with centrally developed programs 
(SAS or SPSS). These strict and uniform rules 
for database construction allowed us to pool all 
country-specific data into one central European 
database. We used SAS software, version 9.3 
(SAS Institute Inc.) for analysis of the central 
database. We replaced values below the LOQ 
by LOQ/2 and transformed biomarker data 
to natural log-transformed concentrations 
(ln). We excluded samples with creatinine 
concentrations < 300 mg/L or > 3,000 mg/L 
from statistical analysis [World Health 
Organization (WHO) 1996]. We calculated 
weighted geometric means (GM) [95% confi-
dence intervals (CIs)] and 90th percentiles 
(P90) (95% CI) so that the countries were 
equally represented, except for Cyprus and 
Luxembourg, which contributed only half. 
Using multiple mixed regression models with 
country as random factor, we identified deter-
minants of exposure biomarkers by including 
pre-specified confounders and significant 
covariates (p < 0.25 from univariate model to 
enter and p < 0.05 to stay) in a stepwise model. 
We expressed urinary biomarkers in micro-
grams per liter with urinary creatinine included 
as confounder. We expressed results as percent 
change (95% CI) of biomarker concentration 
for change of the determinant, after adjust-
ment for all other variables in the model. (For 
detailed methodology and full models, see 
Supplemental Material, “Identification of deter-
minants of exposure,” “Comparison of results 
between countries,” and Table S2.)
To compare biomarker values among 
countries, we compared the GM of a 
country with the European GM by mixed 
linear regression analysis, after adjustment 
for prespecified confounders (Figure 1). To 
visualize similarity between the biomarker 
levels and between different countries and/or 
mothers and children from the same country, 
we generated a heat map using the cluster-
gram function (Matlab, MathWorks Inc.) 
(Figure 2). Hierarchical clustering with 
Euclidean distance metric and average linkage 
was used to generate the hierarchical tree. 
Before analysis, the GM of each country was 
divided by the European GM. The ratio was 
Figure 2. Heat map showing clustering of biomarkers (dendrogram to the left side) and clustering of coun-
tries (dendrogram at the top). Red and blue intensities indicate fold increases and decreases, respectively 
(expressed as log2) in country-specific biomarker concentrations adjusted for age and sex relative to the 
European geometric mean. Abbreviations: Cd, cadmium; COT, cotinine; Hg, mercury. For country codes, 
see Figure 1. Country codes followed by M present concentrations in mothers; country codes followed by 
C present concentrations in children. Gray rectangles bordered in black lines indicate missing data.
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calculated for mothers and children sepa-
rately and was logarithmically transformed 
(log2 base) to obtain symmetry around 0 [= 
log2(1)]. The nearest-neighbor method was 
applied to impute missing data.
To put the results in a health risk context, 
we calculated the proportion of individuals 
with levels above health-based guidance 
values (Aylward et al. 2009a, 2009b; Hays 
et al. 2008; Schulz et al. 2012; WHO 2004).
Results
Determinants of biomarker concentrations. 
Descriptive statistics of 1,844 children and 
mothers included in the study are given in 
Table 1. Participants were equally recruited 
according to predefined strata of sex, age, and 
sampling area in each country. For descrip-
tive statistics of the biomarkers and multiple 
regression models, see Supplemental Material, 
Tables S3–S19.
Fish consumption was the major 
predictor of mercury levels in hair, both in 
children and in mothers (see Supplemental 
Material, Tables S4 and S5). Consumption 
of sea fish, shellfish, or freshwater fish in the 
preceding 4 weeks independently contributed 
to mercury levels in the body. In multiple 
regression models, frequent (several times/
week) compared to sporadic (once/week or 
less) sea fish consumption was associated with 
46% (95% CI: 26, 69%) higher mercury 
levels in children and 51% (95% CI: 34, 71%) 
in mothers; shellfish with 56% (95% CI: 
35, 79%) in children and 38% (95% CI: 
24, 55%) in mothers, freshwater fish with 
23% (95% CI: 8, 39%) in children and 23% 
(95% CI: 11, 37%) in mothers. The GM 
mercury levels of mothers were higher than 
those of the children (Table 2), but levels of 
mothers and children were highly correlated 
(Spearman’s r = 0.72, p < 0.001, n = 1,833). 
Older mothers had 15% (95% CI: 5, 24%) 
higher levels compared to the youngest age 
group (see Supplemental Material, Table S5). 
Table 1. Descriptive statistics of the study population.
Children Mothers
n Median (P25–P75) Minimum–maximum n Median (P25–P75) Minimum–maximum
Age (years) 1,844 8 (7, 10) 5–12 1,844 39 (35, 42) 24–52
Urinary creatinine (mg/L) 1,842 1,053 (784, 1,426) 10–3,120 1,839 1,163 (781, 1,618) 57–3,670
Body height (cm) 1,819 135 (127, 145) 98–170 1,836 166 (161, 170) 145–191
Body weight (kg) 1,820 30 (25, 36) 14–81 1,836 64 (58, 72) 35–186
Body-mass index (kg/m²) 1,811 16.3 (14.9, 18.2) 10.0–36.1 1,833 23.2 (21.1, 26.3) 14.7–62.2
Children Mothers
n Category n (%) n Category n (%)
Sex 1,844 Boy 912 (49.5) 1,844 Woman 1,844 (100)
Girl 932 (50.5)
Area of residence 1,844 Rural 923 (50.1) 1,844 As in children
Urban 921 (49.9)
Highest educational level of the family 1,843 Primary (ISCED 0–2) 166 (9.0) 1,843 As in children
Secondary (ISCED 3–4) 607 (32.9) 
Tertiary (ISCED 5–6) 1,070 (58.1)
Smoking habits 1,844 Smoker 0 (0) 1,844 Daily smoker 283 (15.3)
Nonsmoker 1,844 (100) Occasional smoker 106 (5.7)
Former smoker 401 (21.7)
Never smoker 1,054 (57.2)
ETS at home (nonsmokers only) 1,842 Daily 179 (9.7) 1,450 Yes 162 (11.2) 
Less than daily 130 (7.1) No 1,288 (88.8)
Never 1,533 (83.2)
ETS elsewhere (nonsmokers only) 1,842 Yes 775 (42.1) 1,455 Yes 827 (56.8) 
No 1,067 (57.9) No 628 (43.2)
ETS in last 24 hr (nonsmokers only) 1,840 Yes 232 (12.6) 1,450 Yes 164 (11.3)
No 1,608 (87.4) No 1,286 (88.7)
Children Mothers
n Category n (%) n Category n (%)
Fish consumption (all types) 1,844 Several times/week 442 (24.0) 1,844 Several times/week 483 (26.2)
Once a week or less 1,402 (76.0) Once a week or less 1,361 (73.8)
Consumption of sea fish 1,840 Several times/week 283 (15.4) 1,840 Several times/week 294 (16.0)
Once a week or less 1,557 (84.6) Once a week or less 1,546 (84.0)
Consumption of shellfish 1,820 Several times/week 194 (10.7) 1,826 Several times/week 355 (19.4)
Once a week or less 1,626 (89.3) Once a week or less 1,471 (80.6)
Consumption of freshwater fish 1,815 Several times/week 248 (13.7) 1,818 Several times/week 298 (16.4)
Once a week or less 1,567 (86.3) Once a week or less 1,520 (83.6)
Consumption of seafood products 1,811 Several times/month 94 (5.2) 1,811 Several times/month 154 (8.5)
Once a month or less 1,717 (94.8) Once a month or less 1,657 (91.5)
Consumption of ice cream 1,821 Several times/week 185 (10.2) 1,829 Several times/month 536 (29.3)
Once a week or less 1,636 (89.8) Once a month or less 1,293 (70.7)
Consumption of chewing gum 1,662 Several times/week 578 (34.8) 1,675 Several times/week 626 (37.4)
Once a week or less 1,084 (65.2) Once a week or less 1,049 (62.6)
Use of personal care productsa 1,816 High or moderate 822 (45.3) 1,806 High 861 (47.7)
Low 994 (54.7) Moderate or low 945 (52.3)
PVC in house 1,773 PVC in floors or walls 342 (19.3) 1,773 As in children
No PVC 1,431 (80.7)
Abbreviations: ETS, environmental tobacco smoke; ISCED, International Standard Classification of Education; P25, 25th percentile; P75, 75th percentile; PVC, polyvinyl chloride. 
aUse of personal care products (PCPs) is calculated as a score based on the frequency (never to daily) of nine PCP groups (makeup, eye makeup, shampoo, hair-styling products, body 
lotions and creams, fragrances, deodorant, massage oil, and nail polish). 
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Younger children of 5–8 years showed 8% 
(95% CI: 0, 17%) higher levels compared 
with the older group of 9–11 years (see 
Supplemental Material, Table S4). Participants 
from families with a higher educational level 
(tertiary vs. primary education) had 19% 
(95% CI: 4, 31%) higher levels of mercury 
in children and 25% (95% CI: 13, 36%) 
in mothers.
Cadmium levels in mothers were signifi-
cantly higher in active smoking mothers 
and this was independent of age. The GMs 
were higher in mothers than in children 
(Table 2). Older mothers had 25% (95% CI: 
18, 32%) higher levels than younger mothers 
(see Supplemental Material, Table S9). 
Levels in mothers and children showed a 
low but significant correlation (Spearman’s 
r = 0.24, p < 0.001, n = 1,660). After adjust-
ment for age and smoking, mothers from 
families with a tertiary education had 34% 
(95% CI: 17, 54%) lower levels compared 
with those with a primary education. In 
children, except for age and creatinine, no 
significant determinants were identified (see 
Supplemental Material, Table S8).
T h e  u r i n a r y  l e v e l s  o f  M E H P , 
5OH-MEHP and 5oxo-MEH were highly 
correlated (Pearson’s r > 0.70), so their sum 
was used in the analyses. The GMs of urinary 
phthalate metabolites [except MEP, related 
to use of personal care products (PCPs)] were 
higher in children than in mothers (Table 2). 
Phthalate levels of mothers and children 
were significantly correlated (p < 0.001): 
Spearman’s r ranged between 0.40 and 0.49. 
Multiple regression models (Table 3) showed 
that younger children of 5–8 years showed 
higher levels compared with the older group 
of 9–11 years. Participants from families who 
reported having PVC (polyvinyl chloride) 
floors or walls had significantly increased 
levels of MBzP and MiBP in children and 
mothers and of MnBP in children (Tables 3 
and 4). A small effect for MiBP was seen 
in mothers who reported renovation in the 
house in the previous 2 years. Frequent 
use of PCPs increased urinary MEP levels 
in mothers and children and urinary MiBP 
levels in children. Unexpectedly, urinary 
levels of di(2-ethylhexyl) phthalate (DEHP) 
metabolites and MnBP in mothers were lower 
in frequent PCP users. High consumption of 
ice cream was associated with higher urinary 
levels of DEHP metabolites and MBzP levels 
in children and with higher MnBP and 
MBzP levels in mothers. High consumption 
of chewing gum was related to higher urinary 
levels of DEHP metabolites in children 
and to higher MEP levels in mothers. After 
adjustment for confounders and signifi-
cant covariates, educational level was still a 
predictor of phthalate biomarkers—that is, 
significantly higher urinary levels were found 
for DEHP metabolites in mothers from 
families with a primary education, for MiBP 
(mothers) and MEP (children) in families 
with secondary education, and for MnBP 
(children) in families with tertiary education.
In mothers, the effect of active smoking 
on cotinine levels was dominant (see 
Supplemental Material, Table S7). Levels 
Table 2. European exposure values in children and mothers in the COPHES/DEMOCOPHES study and for those in NHANES.
Biomarker of exposure
COPHES/DEMOCOPHES study NHANESd
n % > LOQa GM (95% CI)b P90 (95% CI)b
n (%) exceeding 
guidance valuec Period n GM (95% CI) P90 (95% CI)
Children
Mercury in hair (μg/g) 1,836 85.9 0.145 (0.139, 0.151) 0.800 (0.698, 0.917) JECFA: n = 25 (1.4) 1999–2000 838 0.12 (0.10, 0.12) 0.41
Urinary cotinine (μg/L) 1,818 57.6 0.80 (0.76, 0.84) 4.90 (3.90, 6.16) — — — — —
Urinary cadmium (μg/L) 1,698 70.1 0.071 (0.069, 0.074) 0.220 (0.209, 0.232) HBM-I: n = 6 (0.4) 
HBM–II: n = 0 (0.0) 
BE: n = 0 (0.0)
2009–2010 415 0.057  
(0.053, 0.061)
0.130  
(0.120, 0.160)
Urinary DEHP metabolites 
(μg/L)e 
1,816 85.6 47.6 (46.0, 49.3) 137 (126, 150) HBM-I: n = 12 (0.6) 
BE: n = 53 (2.9)
2009–2010 415 MEHP: 1.64 (1.45, 1.85)  
5OH-MEHP: 15.0 (13.2, 17.1)  
5-oxo-MEHP: 9.87 (8.72, 11.0)  
∑(GM) = 26.5
Urinary MEP (μg/L) 1,816 98.0 34.4 (32.8, 36.0) 159 (138, 183) BE: n = 0 (0.0) 2009–2010 415 35.2 (31.2, 39.8) 151 (114, 207)
Urinary MBzP (μg/L) 1,816 95.2 7.1 (6.8, 7.5) 27.8 (25.2, 30.6) BE: n = 0 (0.0) 2009–2010 415 11.6 (9.51, 14.1) 63.9 (47.4, 76.8)
Urinary MnBP (μg/L) 1,355 99.9 34.8 (33.5, 36.2) 95.5 (87.3, 104.5) — 2009–2010 415 21.7 (19.0, 24.8) 83.8 (59.6, 121)
Urinary MiBP (μg/L) 1,355 99.8 45.4 (43.6, 47.3) 131 (117, 147) — 2009–2010 415 10.2 (9.10, 11.4) 35.7 (28.8, 46.9)
Mothers
Mercury in hair (μg/g) 1,839 90.5 0.225 (0.216, 0.234) 1.200 (1.068, 1.349) JECFA: n = 62 (3.4) 1999–2000 1,726 0.20 (0.16, 0.24) 1.11
Urinary cotinine (μg/L) 1,800 62.4 2.75 (2.41, 3.14) 1,182 (974, 1,434) — — — — —
Urinary cadmium (μg/L) 1,685 93.8 0.219 (0.211, 0.228) 0.620 (0.580, 0.663) HBM-I: n = 49 (2.9) 
HBM–II: n = 0 (0.0) 
BE: n = 26 (1.5)
2009–2010 1,450 0.188  
(0.172, 0.206)
0.740  
(0.620, 0.880)
Urinary DEHP metabolites 
(μg/L)e
1,800 81.6 29.2 (28.1, 30.3) 91 (84, 100) HBM-I: n = 19 (1.0) 
BE: n = 28 (1.5)
2009–2010 1,350 MEHP: 1.39 (1.21, 1.60)  
5OH-MEHP: 11.0 (9.58, 12.8) 
5-oxo-MEHP: 7.09 (6.17, 8.14)  
∑(GM) = 19.5
Urinary MEP (μg/L) 1,800 95.2 48.2 (45.6, 51.0) 252 (221, 287) BE: n = 0 (0.0) 2009–2010 1,350 67.8 (60.3, 76.4) 548 (392, 675)
Urinary MBzP (μg/L) 1,800 91.8 4.5 (4.3, 4.7) 17.7 (16.1, 19.5) BE: n = 0 (0.0) 2009–2010 1,350 6.04 (5.38, 6.77) 29.3 (24.5, 36.9)
Urinary MnBP (μg/L) 1,347 99.4 23.9 (23.0, 24.9) 66.2 (60.5, 72.4) — 2009–2010 1,350 14.7 (13.1, 16.5) 57.7 (52.7, 63.9)
Urinary MiBP (μg/L) 1,347 99.4 30.1 (28.9, 31.4) 88 (81, 96) — 2009–2010 1,350 7.50 (6.68, 8.43) 29.1 (25.3, 33.5)
Abbreviations: BE, biomonitoring equivalent; DEHP, di(2-ethylhexyl)phthalate; ∑(GM), sum of geometric means of MEHP, 5OH-MEHP, and 5oxo-MEHP; HBM-I, human biomonitoring 
value I; HBM-II, human biomonitoring value II; JECFA, Joint FAO/WHO Expert Committee on Food Additives; LOQ, limit of quantification; MBzP, monobenzyl phthalate; MEP, monoethyl 
phthalate; MiBP, monoisobutyl phthalate; MnBP, mono-n-butyl phthalate; P90, 90th percentile. 
aLOQs ranged from 0.001 to 0.137 μg/g for mercury in hair, 0.1–1.2 μg/L for urinary cotinine, 0.001–0.2 μg/L for urinary cadmium, 0.3–3.9 μg/L for urinary MEHP, 0.1–9.2 μg/L for urinary 
5OH-MEHP, 0.1–6.2 μg/L for urinary 5oxo-MEHP, 0.5–11 μg/L for urinary MEP, 0.2–5 μg/L for urinary MBzP, 0.5–4.4 μg/L for urinary MnBP, and 0.5–4.9 μg/L for urinary MiBP. bGeometric 
means and 90th percentiles are weighed but not adjusted for confounders (see “Methods”). cHealth-based exposure values are available for mercury: JECFA guideline = 2.3 μg/g 
(WHO 2004); cadmium: HBM-I in children = 0.5 μg/L; HBM-II in children = 1 μg/L; HBM-I in adults = 1.0 μg/L; HBM-II in adults = 4.0 μg/L (Schulz et al. 2012); BE in children and in 
mothers = 1.2 μg/L (Hays et al. 2008); phthalate metabolites: HBM-I value for DEHP metabolites are based on the sum of 5OH-MEHP and 5oxo-MEHP and equal 500 μg/L in children and 
300 μg/L in adults (Schulz et al. 2012); BEs for DEHP metabolites are based on the sum of MEHP, 5OH–MEHP, and 5oxo-MEHP: 260 μg/L in both children and mothers (Aylward et al. 
2009a); BE for MEP in mothers and children = 18 mg/L (Aylward et al. 2009b); BE for MBzP in children and adults = 3.8 mg/L (Aylward et al. 2009b). dNHANES: data for urinary cadmium 
and urinary phthalate metabolites from The Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables, March 2013 (Centers for Disease Control and 
Prevention 2013); data for mercury in hair from McDowell et al. (2004). Data for COPHES/DEMOCOPHES children are compared with NHANES subgroup “Age group 6–11 years”; data 
for COPHES/DEMOCOPHES mothers are compared with NHANES subgroup “Females.” eUrinary DEHP metabolites: sum of MEHP, 5OH-MEHP, and 5oxo-MEHP.
Den Hond et al.
260 volume 123 | number 3 | March 2015 • Environmental Health Perspectives
in mothers and children correlated strongly 
(Spearman’s r = 0.71, p < 0.001, n = 1,777). 
The younger children of 5–8 years showed 
16% (8, 25%) higher levels compared to the 
older group of 9–11 years (see Supplemental 
Material, Table S6). In children, environ-
mental tobacco smoke (ETS) at home was the 
strongest predictor. Compared with children 
who were never exposed to ETS at home, 
children with daily exposure had five times 
higher values [504% (95% CI: 429, 593%)], 
and children with less than daily exposure 
had almost double values [181% (95% CI: 
155, 211%)]. Exposure to ETS in other 
places than home resulted in 19% (95% CI: 
Table 3. Determinants of exposure to urinary phthalate metabolites (μg/L): multiple regression models in children.
Parameters Category
Estimate (95% CI) for change (multiplicative factor)
DEHP MEP MBzP MnBP MiBP
Agea 5–8 years 1.19 (1.11, 1.27) 1.15 (1.04, 1.26) 1.15 (1.06, 1.26) 1.15 (1.07, 1.24) 1.19 (1.10, 1.28)
9–11 years 1.00 1.00 1.00 1.00 1.00
Sexa Boys NS NS NS 0.91 (0.85, 0.98) 0.92 (0.85, 0.99)
Girls 1.00 1.00
Urinary creatinine levela 300–900 mg/L 0.46 (0.42, 0.51) 0.41 (0.36, 0.47) 0.41 (0.37, 0.47) 0.45 (0.41, 0.50) 0.45 (0.40, 0.50)
900–1,500 mg/L 0.75 (0.69, 0.83) 0.68 (0.61, 0.77) 0.69 (0.62, 0.78) 0.73 (0.66, 0.81) 0.72 (0.65, 0.80)
1,500–3,000 mg/L 1.00 1.00 1.00 1.00 1.00
Urine sampling period < 10 hr NS 1.20 (1.06, 1.35) NS NS NS
10–11 hr 1.14 (1.02, 1.29)
≥ 11 hr 1.00
Morning urine Yes NS NS 1.98 (1.17, 3.36) NS NS
No 1.00
Educational level of the family Primary NS 0.91 (0.81, 1.03) NS 0.91 (0.81, 1.03) NS
Secondary 0.89 (0.82, 0.97) 0.89 (0.82, 0.97)
Tertiary 1.00 1.00
Use of personal care productsb Moderate to high use NS 1.24 (1.13, 1.37) NS NS 1.13 (1.03, 1.23)
Low use 1.00 1.00
Ice cream consumption Several times/week 1.12 (1.01, 1.25) NS 1.18 (1.02, 1.36) NS NS
Once/week or less 1.00 1.00
Gum consumption Several times/week 1.10 (1.02, 1.18) NS NS NS NS
Once/week or less 1.00
PVC in floors/walls Yes NS NS 1.50 (1.34, 1.68) 1.19 (1.08, 1.32) 1.22 (1.09, 1.35) 
No 1.00 1.00 1.00
NS, not significant. For phthalate abbreviations, see Table 2. 
aThe confounders urinary creatinine level, sex, and age were forced in the multiple regression models, even if not significant. bUse of personal care products (PCPs) is calculated as a 
score based on the frequency (never to daily) of nine PCP groups (makeup, eye makeup, shampoo, hair-styling products, body lotions and creams, fragrances, deodorant, massage oil, 
and nail polish).
Table 4. Determinants of exposure to urinary phthalate metabolites (μg/L): multiple regression models in mothers.
Parameters Category
Estimate (95% CI) for change (multiplicative factor)
DEHP MEP MBzP MnBP MiBP
Agea ≤ 35 years NS NS NS 0.81 (0.73, 0.89) NS
35–40 years 0.93 (0.86, 1.01)
> 40 years 1.00
Body mass index Normal Weight NS NS NS 1.15 (1.02, 1.29) NS
Overweight 1.09 (0.96, 1.24)
Obese 1.00
Urinary creatinine levela 300–900 mg/L 0.35 (0.32, 0.38) 0.32 (0.28, 0.37) 0.33 (0.30, 0.37) 0.35 (0.32, 0.38) 0.38 (0.35, 0.41)
900–1,500 mg/L 0.62 (0.57, 0.68) 0.63 (0.55, 0.72) 0.59 (0.54, 0.65) 0.60 (0.55, 0.66) 0.61 (0.56, 0.67)
1,500–3,000 mg/L 1.00 1.00 1.00 1.00 1.00
Urine sampling period < 7 hr 0.87 (0.79, 0.97) NS NS NS NS
7–9 hr 0.97 (0.88, 1.06)
≥ 9 hr 1.00
Educational level of the family Primary 1.20 (1.05, 1.37) NS NS NS 1.09 (0.97, 1.23)
Secondary 1.04 (0.96, 1.13) 1.11 (1.02, 1.21)
Tertiary 1.00 1.00
Use of personal care productsb High use 0.91 (0.84, 0.98) 1.40 (1.25, 1.56) NS 0.92 (0.86, 0.99) NS
Moderate to low use 1.00 1.00 1.00
Ice cream consumption Several times/month NS NS 1.13 (1.03, 1.24) 1.10 (1.01, 1.19) NS
Once/month or less 1.00 1.00
Gum consumption Several times/week NS 1.19 (1.06, 1.34) NS NS NS
Once/week or less 1.00
PVC in floors/walls Yes NS NS 1.32 (1.19, 1.47) NS 1.15 (1.04, 1.26)
No 1.00 1.00
Renovation in house Yes NS NS NS NS 1.08 (1.00, 1.16)
No 1.00
NS, not significant. For phthalate abbreviations, see Table 2. 
aThe confounders urinary creatinine level and age were forced in the multiple regression models, even if not significant. bUse of personal care products (PCPs) is calculated as a score 
based on the frequency (never to daily) of nine PCP groups (makeup, eye makeup, shampoo, hair-styling products, body lotions and creams, fragrances, deodorant, massage oil, and 
nail polish). 
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10, 29%) higher values. Compared with 
children from families with a tertiary educa-
tion, those with a secondary education had 
20% (95% CI: 10, 30%) higher cotinine levels 
in urine, and those with primary education had 
49% (95% CI: 29, 72%) higher values.
The geographical aspect. Residence in 
urban or rural area was not a significant deter-
minant of internal exposure at the European 
Union level. Only mercury in hair showed, 
independently of fish consumption, higher 
levels in urban areas compared with rural areas: 
35% (95% CI: 23, 47%) higher in children 
and 30% (95% CI: 19, 41%) in mothers (see 
Supplemental Material, Tables S4 and S5).
The average biomarker concentrations 
varied significantly among the European 
countries. This holds for the unadjusted data 
(see Supplemental Material, Tables S20–S35) 
and for data after adjustment for age, sex, and 
weighting for equal group sizes (Figure 1). The 
average biomarker concentrations of mercury in 
hair of Spanish and Portuguese children were, 
respectively, six and seven times higher than 
the European average. Cadmium varied less 
among the countries: Average urinary cadmium 
levels in Polish and Slovak mothers were 
respectively 1.9 and 1.7 times higher than the 
European average. In Romania and Hungary, 
average cotinine levels were, respectively, 
2.4 and 2.2 times higher than the European 
average, reflecting the weak antismoking legisla-
tion in these countries. Swedish children had, 
on average, three times higher urinary MBzP 
levels than the average European value. Slovak 
children had almost twice the average European 
biomarker concentrations of DEHP metabo-
lites, and Polish children showed the highest 
average levels of MnBP and MiBP. Average 
MEP levels in Spain were six times higher than 
the European average. The heat map (Figure 2) 
shows that biomarker data from mothers and 
children clustered together except in the Czech 
Republic and the Slovak Republic. Overall the 
biomarker clustering followed geographical 
grouping. The Southern European countries 
(Spain, Portugal) clustered separately from 
the other countries; Eastern European coun-
tries (Romania, Hungary, Poland, the Czech 
Republic, and the Slovak Republic) formed 
a further cluster; Western European coun-
tries (Germany, Belgium, Luxembourg, and 
Denmark) also showed fairly good resemblance.
Although the sampling frame of the 
European biomonitoring program differs 
from that of the U.S. national program, the 
geometric means and P90 of COPHES/
DEMOCOPHES are well in line with the 
results obtained in NHANES (Centers for 
Disease Control and Prevention 2013; 
McDowell et al. 2004) (Table 2). For MiBP, 
higher values were observed in Europe 
compared with the United States (factor 
3–4), in both mothers and children (Table 2). 
Differences for other biomarkers were modest, 
with a trend in Europe for lower biomarker 
concentrations of MBzP and MEP, higher 
concentrations of MnBP and DEHP, and 
similar levels for cadmium and mercury.
Available health-based guidance values 
allow us to put the observed biomarker 
concentrations in a risk context. Few partici-
pants exceeded these values (Table 2). The 
P90 of the biomarker values is far below the 
guidance values; only the urinary cadmium 
P90 of mothers and children was within a 
factor 2 of the concentration below which 
no risk for adverse health effects is expected 
(Schulz et al. 2012), and for mercury they are 
below a factor 3.
Discussion
This first Europe-wide program provides 
biomarker data from mothers and children 
of 17 European countries. Because we 
recruited in one rural and one urban area 
per country, our sample was not representa-
tive for the European Union population. Yet 
the recruited sample had a smoking behavior 
similar to that of the average European popula-
tion (Currie et al. 2012). Also, the countries 
ranked in their reported fish consumption 
here according to national statistics (Food and 
Agriculture Organization 2013). The educa-
tional level of the participants was skewed 
toward a higher educational level. The study 
design allowed us to conclude that exposure to 
mercury, cadmium, phthalates, and nicotine is 
widespread in the European population.
Differences in environment and lifestyle 
influenced individual biomarker values and 
country-specific averages. If we compared 
average levels among countries, the biomarker 
patterns varied according to geographic trends. 
Yet few study participants exceeded the avail-
able health-based guidance values. The major 
strength of our study is the comparable data 
from 17 European countries produced through 
a harmonized process, including the use of a 
commonly developed protocol, intensive 
training and capacity building for field work, 
chemical analyses, reporting and commu-
nication, as well as stringent quality control 
programs for chemical and data analysis. This 
allowed us to measure both well-known pollut-
ants such as cadmium, cotinine, or mercury 
and emerging chemicals such as phthalates.
Our study identified younger children as 
more exposed than older children to phthalates 
(except MEP), cotinine, and mercury. These 
results are in line with U.S. data for exposure to 
phthalates (Silva et al. 2004) and ETS (Bernert 
et al. 2010). The underlying reasons cannot be 
derived from this study but may be explained 
by higher exposure relative to body size through 
inhalation of dust or food intake; by typical 
exposure patterns in children, such as contact 
with toys, more time spent on the floor, and 
more frequent hand-to-mouth contact; or by 
differences in metabolism. Additionally, the 
higher cotinine levels in younger children 
might be attributable to the fact that they 
spend more time at home, and thus may be 
more exposed to nicotine, since smoking in 
public buildings is much more controlled than 
in private homes. We observed a significant 
influence of social class (represented by the 
highest educational level within the family) on 
each of the biomarker levels even after adjust-
ment for confounders and significant covari-
ates: Mercury level in hair increased in children 
and mothers if social class was higher, whereas 
cotinine, cadmium, and phthalate metabolites 
were lower with increasing educational level of 
the family. Perhaps underlying lifestyle factors 
that vary with socioeconomic status and that 
were not considered in the questionnaires may 
account for these findings. These associations 
between social class and biomarker concentra-
tions are in line with U.S. data (Tyrrell et al. 
2013) and may be mediated partly by smoking, 
occupation, and diet (fish consumption, 
local food, convenience food). Our findings 
thus indicate that public health remediation 
measures to decrease environmental exposure 
and disease burden within a society should be 
stratified according to age groups and social 
strata within the population.
Fish consumption and social status 
were identified as important and indepen-
dent determinants of mercury levels, both 
in mothers and children. This is in line 
with results from several populations with 
moderate to high fish consumption (Deroma 
et al. 2013). Mercury levels in children and 
in women of childbearing age are important 
parameters to monitor because pre- and post-
natal mercury exposure, even at low levels, has 
adverse neurodevelopmental effects (Karagas 
et al. 2012). Although several high fish–
consuming countries such as France, Finland, 
Lithuania, Malta, and Italy are not partici-
pating in DEMOCOPHES at present, 1.4% 
of the children and 3.4% of the mothers in 
our study population had mercury levels above 
the JECFA/WHO provisional threshold value 
of 2.3 μg/g hair (WHO 2004). This propor-
tion differs considerably by country, with 
0% of participants exceeding the threshold 
in most Northern and Central European 
countries and up to 33% of the mothers with 
levels above the safe dose in countries with 
high fish consumption, with implications for 
loss of IQ points and costs (Bellanger et al. 
2013). If these data urge policy makers to 
take actions, current biomarker concentra-
tions can be used as baseline for follow-up, 
both for the exposure of the population and 
the environment. The major exposure route 
for DEHP is food (Koch and Calafat 2009). 
Therefore, we were not surprised to find an 
association between DEHP metabolites with 
Den Hond et al.
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chewing gum and ice cream consumption. 
Most probably, these two food items are not 
specific sources, but rather represent predi-
lection for flavored, packaged, or processed 
food, and thus may be proxies for conve-
nience food. The association between urinary 
MBzP and PVC materials in the home is in 
accordance with recent findings in children 
(Carlstedt et al. 2012). Although high-
molecular-weight phthalates such as DEHP 
are the major phthalates used in PVC, no 
association was found between the presence of 
PVC at home and urinary DEHP metabolites. 
Given that DEHP exposure is dominated 
by foods (Koch et al. 2013) and that DEHP 
house dust does not correlate with DEHP 
body burden (Becker et al. 2004), a significant 
correlation was not really expected. The lower 
levels of DEHP metabolites and MnBP in 
mothers who were high PCP users were not 
expected and may relate to cross-correlation 
with other personal habits. The relative levels 
of phthalate metabolites differ substantially 
among countries, which points to different 
sources, products on the market, or behavior 
characteristics. Despite legal restrictions on 
the use of DEHP, di-n-butyl phthalate, and 
diisobutyl phthalate as imposed by European 
Union directives, these compounds are still 
ubiquitous in Europeans. They are short-lived 
in the body, implying that exposures to these 
compounds are still part of current daily life. 
Diethyl phthalate, one of the principal phthal-
ates in cosmetic products (Koch and Calafat 
2009), is not yet restricted. High levels of its 
metabolite MEP were found.
The health impact of cigarette smoking 
is well documuented (U.S. Department of 
Health and Human Services 2004). The home 
environment appears to be the most impor-
tant predictor of the cotinine levels in children. 
Further awareness of parents therefore is 
needed. The importance of anti-smoking legis-
lation pays off, as countries with stronger legis-
lation that has been longer in place showed the 
lowest cotinine levels (European Union 2011). 
The effectiveness of anti-smoking legislation on 
health outcomes has been demonstrated on a 
population level (Cox et al. 2013).
Conclusion
This HBM study presents the first steps, 
for Europe as a whole, to register internal 
chemical exposures at the individual level. 
Although the sampling protocol is not yet 
representative for the geographical distribu-
tion of the population in the country, the 
results show remarkable differences in the 
biomarker concentration profiles by country 
residence. Personal habits and lifestyle are 
strong determinants of internal exposure. 
The harmonized protocols and stringent 
quality control measures ensure that these 
are true differences, not related to variability 
in protocols, analytical measurements, or 
interpretation. These data offer policy makers 
direct means by which to evaluate whether 
implementation of protective measures and 
legislation related to chemicals are adequate 
to protect the health of the entire population 
or whether they need to be adjusted.
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